FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955535780> ?p ?o ?g. }

• W2955535780 endingPage "1461" @default.
• W2955535780 startingPage "1461" @default.
• W2955535780 abstract "Abstract In vitro transcribed (IVT) mRNA is forming a new basis of drug delivery as it can be synthetically engineered to express the desired protein in lesser time and be more specific than the other 2 types of antigens. Using DNA (coding for proto-oncogenes) for immunization poses a risk for host cell transformation into a malignant one and hence proto-oncogenes would express for a longer time. Therefore, mRNA was considered for cancer immunotherapy as it does not integrate into the host cell's genome, so no question of insertional mutagenesis arises. Our main aim is to develop a stable mRNA system working both in vitro and in vivo and then use this system to develop mRNA vaccines. The stability of IVT mRNA can be increased by changing the 3' and 5' UTRs, adding a 5'cap and 3' poly-A tail which could even increase their half-life to a few days. For creating a stable mRNA working system in vitro, EGFP-2A gene was cloned along with the AdsA (Staphylococcus aureusgene important for infection) in a vector backbone with TMV 3’UTR and 5’UTR. The mRNA created in vitro was with modified uridine and cap 1 structure and transfected to the mammalian cell lines. This transfection was further enhanced by using liposome created in the lab (using some cationic and helper lipids in different ratios) by film rehydration method. The expression of luciferase mRNA was then detected in mice by live imaging indicating that the mRNA system is stable in vivo. Further, to direct the mRNA encoded antigens to MHC1 and MHC2 pathways they were tagged with a htPA secretion tag and MHC1 targeting signal along with a 3XFLAG tag. We tried various mode of injections with AdsA mRNA to have a profile of ELISPOT with differently exposed mRNA (in vivo in mice). Now we are focussing on some neo antigens for tumor to be used as. Avaccine in the form of mRNA. Citation Format: Smriti Arya, Qiubin Lin, Nan Zhou, Jiandong Huang. mRNA therapeutics against cancers and infectious diseases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1461." @default.
• W2955535780 created "2019-07-12" @default.
• W2955535780 creator A5028104614 @default.
• W2955535780 creator A5033281260 @default.
• W2955535780 creator A5043731980 @default.
• W2955535780 creator A5066506814 @default.
• W2955535780 date "2019-07-01" @default.
• W2955535780 modified "2023-10-02" @default.
• W2955535780 title "Abstract 1461: mRNA therapeutics against cancers and infectious diseases" @default.
• W2955535780 doi "https://doi.org/10.1158/1538-7445.am2019-1461" @default.
• W2955535780 hasPublicationYear "2019" @default.
• W2955535780 type Work @default.
• W2955535780 sameAs 2955535780 @default.
• W2955535780 citedByCount "0" @default.
• W2955535780 crossrefType "journal-article" @default.
• W2955535780 hasAuthorship W2955535780A5028104614 @default.
• W2955535780 hasAuthorship W2955535780A5033281260 @default.
• W2955535780 hasAuthorship W2955535780A5043731980 @default.
• W2955535780 hasAuthorship W2955535780A5066506814 @default.
• W2955535780 hasConcept C104317684 @default.
• W2955535780 hasConcept C105580179 @default.
• W2955535780 hasConcept C107635520 @default.
• W2955535780 hasConcept C141231307 @default.
• W2955535780 hasConcept C153911025 @default.
• W2955535780 hasConcept C202751555 @default.
• W2955535780 hasConcept C207001950 @default.
• W2955535780 hasConcept C54009773 @default.
• W2955535780 hasConcept C54355233 @default.
• W2955535780 hasConcept C86803240 @default.
• W2955535780 hasConcept C89604277 @default.
• W2955535780 hasConcept C91779695 @default.
• W2955535780 hasConcept C95444343 @default.
• W2955535780 hasConceptScore W2955535780C104317684 @default.
• W2955535780 hasConceptScore W2955535780C105580179 @default.
• W2955535780 hasConceptScore W2955535780C107635520 @default.
• W2955535780 hasConceptScore W2955535780C141231307 @default.
• W2955535780 hasConceptScore W2955535780C153911025 @default.
• W2955535780 hasConceptScore W2955535780C202751555 @default.
• W2955535780 hasConceptScore W2955535780C207001950 @default.
• W2955535780 hasConceptScore W2955535780C54009773 @default.
• W2955535780 hasConceptScore W2955535780C54355233 @default.
• W2955535780 hasConceptScore W2955535780C86803240 @default.
• W2955535780 hasConceptScore W2955535780C89604277 @default.
• W2955535780 hasConceptScore W2955535780C91779695 @default.
• W2955535780 hasConceptScore W2955535780C95444343 @default.
• W2955535780 hasIssue "13_Supplement" @default.
• W2955535780 hasLocation W29555357801 @default.
• W2955535780 hasOpenAccess W2955535780 @default.
• W2955535780 hasPrimaryLocation W29555357801 @default.
• W2955535780 hasRelatedWork W1995847322 @default.
• W2955535780 hasRelatedWork W2038160098 @default.
• W2955535780 hasRelatedWork W2074050642 @default.
• W2955535780 hasRelatedWork W2130669936 @default.
• W2955535780 hasRelatedWork W2171277769 @default.
• W2955535780 hasRelatedWork W2424525284 @default.
• W2955535780 hasRelatedWork W2564222003 @default.
• W2955535780 hasRelatedWork W2725195091 @default.
• W2955535780 hasRelatedWork W3030472574 @default.
• W2955535780 hasRelatedWork W4232949972 @default.
• W2955535780 hasVolume "79" @default.
• W2955535780 isParatext "false" @default.
• W2955535780 isRetracted "false" @default.
• W2955535780 magId "2955535780" @default.
• W2955535780 workType "article" @default.